The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Autologous HSCT for severe progressive multiple sclerosis in a multicenter trial: impact on disease activity and quality of life
Open accessAbstract
Hematopoietic stem cell transplantation (HSCT) has been proposed for the treatment of severe multiple sclerosis (MS). In a phase 2 multicenter study we selected 19 non-primary progressive MS patients showing high disease activity on the basis of both brain magnetic resonance imaging (MRI) and sustained clinical deterioration despite conventional treatments. After stem cell mobilization with cyclophosphamide (CY) and filgrastim, patients were conditioned with BCNU (1,3-bis(2-chloroethyl)-1-nitrosourea), cytosine arabinoside, etoposide, and melphalan (BEAM) followed by antithymocyte globulin (ATG). Unmanipulated peripheral blood stem cells (PBSCs) were then infused. No maintenance treatment was administered with a median follow-up of 36 months (range, 12 to 72 months). All patients showed clinical stabilization or improvement; 3 subsequently deteriorated, 1 beyond the baseline. No MRI active lesions were detected after the HSCT except in 1 patient who showed a new lesion at 4.5 years. Infections were limited and restricted to 3 months after HSCT. Health-related quality of life was assessed through the 54-item MS quality of life (MSQOL-54) questionnaire, showing a statistically significant improvement in both composite scores and in most of the individual domains. HSCT is able to induce a prolonged clinical stabilization in severe progressive MS patients, resulting in both sustained treatment-free periods and quality of life improvement.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A health-related quality of life measure for multiple sclerosis
Vickrey, B. G., Hays, R. D., Harooni, R., Myers, L. W., & Ellison, G. W. (1995) · Quality of Life Research · doi:10.1007/bf02260859 · Cited by 1,132
Cited by
Lymphoid neogenesis in chronic inflammatory diseases
Aloisi, F., & Pujol-Borrell, R. (2006) · Nature Reviews Immunology · doi:10.1038/nri1786 · Cited by 908
Mitchell, A. J., Benito-León, J., González, J.-M. M., & Rivera-Navarro, J. (2005) · The Lancet Neurology · doi:10.1016/s1474-4422(05)70166-6 · Cited by 519
Muraro, P. A., Douek, D. C., Packer, A., Chung, K., Guenaga, F. J., Cassiani-Ingoni, R., Campbell, C., Memon, S., Nagle, J. W., Hakim, F. T., et al. (2005) · The Journal of Experimental Medicine · doi:10.1084/jem.20041679 · Cited by 502
(PDWP), O. B. O. T. E. A. D. W. P. (. A. P. D. W. P., Snowden, J. A., Saccardi, R., Allez, M., Ardizzone, S., Arnold, R., Cervera, R., Denton, C., Hawkey, C., Labopin, M., et al. (2012) · Bone Marrow Transplantation · doi:10.1038/bmt.2011.185 · Cited by 328
Self-citationAutologous haematopoietic stem cell transplantation for treatment of multiple sclerosis
Muraro, P. A., Martin, R., Mancardi, G. L., Nicholas, R., Sormani, M. P., & Saccardi, R. (2017) · Nature Reviews Neurology · doi:10.1038/nrneurol.2017.81 · Cited by 304
Self-citation
Metadata
- Authors
- Saccardi, R.
- Venue
- Blood
- Publisher
- American Society of Hematology
- Published
- 2005-03-15
- Volume
- 105
- Issue
- 6
- Pages
- 2601-2607
- ISSN
- 0006-4971 (ISSN-L)
- 1528-0020
- OpenAlex
- W2146183778
- Cited by
- 161
- References
- 1
- FWCI
- 8.67
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Autologous HSCT for severe progressive multiple sclerosis in a multicenter trial: impact on disease activity and quality of life. https://app.cochat.ai/papers/10.1182/blood-2004-08-3205
- The paper
- Saccardi, R. (2005). Autologous HSCT for severe progressive multiple sclerosis in a multicenter trial: impact on disease activity and quality of life. Blood. https://doi.org/10.1182/blood-2004-08-3205
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.